R-Tech Ueno
10F, Yamato Life Insurance Building
1-1-7 Uchisaiwaicho, Chiyoda-ku
Tokyo
100-0011
Tel: 81-3-3596-8011
Fax: 81-3-3596-8023
Email: info@rtueno.co.jp
48 articles about R-Tech Ueno
-
Sucampo Provides Update To 2015 And Confirms 2016 Financial Guidance Post Closing Of R-Tech Ueno Acquisition
1/7/2016
-
Sucampo Completes Acquisition Of R-Tech Ueno
12/7/2015
-
Sucampo Offers to Buy R-Tech Ueno for $278 Million
8/26/2015
-
R-Tech Ueno: Announcement On Collaborative Development Of Therapeutic Agent For Cerebral Infarction Utilizing VAP-1 Inhibitor (RTU-009) With Autonomous University Of Barcelona And Vall d'Hebron Institute Of Research
6/8/2015
-
R-Tech Ueno: Announcement On Completion Of The Phase I Single-Dose Clinical Trial for the Novel VAP-1 Inhibitor RTU-1096
5/26/2015
-
R-Tech Ueno: Announcement On Collaborative Development Of Therapeutic Agent For Diabetic Retinopathy And Diabetic Macular Edema Utilizing VAP-1 Inhibitor (RTU-1096) With Hokkaido University
5/18/2015
-
R-Tech Ueno, Sucampo Dissolve Unoprostone Pacts
5/7/2015
-
R-Tech Ueno: Announcement On Acquisition Of The Right To Develop And Commercialize DE-105 From Santen Pharmaceutical
4/27/2015
-
Sucampo Pharmaceuticals, Inc. To Return All Licenses For Unoprostone Isopropyl To R-Tech Ueno
3/9/2015
-
R-Tech Ueno: The End Of A Phase 3 Clinical Study And Preliminary Findings From A Phase 3 Of Unoprostone (Development Code UF-021) For Treatment Of Retinitis Pigmentosa
3/9/2015
-
R-Tech Ueno Received Orphan Drug Designation For Unoprostone Isopropyl (Development Code:UF-021) For The Treatment Of Retinitis Pigmentosa From MHLW
11/25/2014
-
R-Tech Ueno: Lawsuit Claiming Infringement Of AMITIZA® Capsules Patents
11/13/2014
-
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye
11/10/2014
-
R-Tech Ueno: Sucampo Pharmaceuticals, Inc. And Takeda Enter Into Global Licensing Agreement For AMITIZA® (Lubiprostone)
10/23/2014
-
R-Tech Ueno: Announcement Of Initiation Of The Phase I Clinical Trial For The Novel VAP-1 Inhibitor RTU-1096
10/20/2014
-
R-Tech Ueno: Settlement Agreement That Resolves Patent Litigation In U.S. Related To AMITIZA® And Company Receives Additional Paragraph IV Notice
10/10/2014
-
R-Tech Ueno: Announcement Of Collaborative Research With Keio University For Treatment Of Graft-Versus-Host Disease (GVHD)
3/11/2014
-
R-Tech Ueno Release: Announcement of the Completion of Stage I and the Start of Enrollment for Stage II of the Phase I/II Clinical Trial of Genetically Recombinant Human Serum Albumin (Code: RU-101) Ophthalmic Solution for the Treatment of Severe Dry Eye
11/8/2013
-
R-Tech Ueno: Start of the Patient Enrollment of a Phase I/II Clinical Study of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) in U.S. for the Treatment of Severe Dry Eye
5/20/2013
-
R-Tech Ueno Receives FDA IND Approval for RU-101 (r-HSA) to Treat Severe Dry Eye
4/26/2013